If patients were CYFRA 21 − 1 positive and Ki67 high, it indicates that those patients have shorter survival times, which may provide new insights into EGFR wide-type NSCLC therapy and follow-up. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.